Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission.

Read More »

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

AstraZeneca and Merck & Co.’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom